GlassScriptPhysician profile
Nikhil Manjunath
NPI 1396241154
$859.18
in general payments reported to CMS, 2019-2025
17 companies · $586 in 2025
The $586 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $110 · 2024: $163 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $164.53 | 2023-2025 | Enhertu, Lynparza |
| Beigene USA, INC. | $133.01 | 2023-2025 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $126.11 | 2025 | |
| Janssen Biotech, INC. | $56.37 | 2024-2025 | Erleada, Akeega, Tecvayli |
| Abbvie INC. | $45.28 | 2025 | |
| Genzyme Corporation | $38.56 | 2025 | |
| Genentech, INC. | $35.64 | 2025 | Itovebi |
| Jazz Pharmaceuticals INC. | $34.10 | 2025 | |
| Adc Therapeutics America, INC. | $31.27 | 2024 | |
| Daiichi Sankyo INC. | $29.75 | 2025 | Vanflyta |
| Takeda Pharmaceuticals U.S.A., INC. | $29.66 | 2025 | Iclusig |
| Regeneron Healthcare Solutions, INC. | $24.88 | 2025 | Libtayo |
| Lilly USA, LLC | $23.66 | 2025 | Verzenio |
| Incyte Corporation | $23.39 | 2023 | Jakafi |
| Gilead Sciences, INC. | $22.10 | 2025 | Trodelvy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $21.36 | 2025 | Venclexta |
| Beone Medicines USA, INC. | $19.51 | 2025 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Manjunath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.